CDKN2A and cutaneous melanoma: Alterations in Cdkn2a and other cell cycle regulators are almost universal in cutaneous melanomas, and they may frequently have additional mutations detected in brain metastases.6,17 Thus, inhibitors against components of this pathway (ie, CDK4/6 inhibitors) may also be rational to evaluate in MBMs (ie, NCT02308020).